Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Meiji gets Asian rights to Acadia's schizophrenia compounds; terminated

Executive Summary

CNS and ophthalmic drug discovery firm Acadia Pharmaceuticals has licensed Meiji Seika Kaisha (operates food and pharmaceutical businesses) exclusive rights to develop a group of preclinical compounds for schizophrenia and similar cognitive diseases and sell them in Japan and other Asian countries.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies